1、-II$* (csco) mg5IjJ.ifilii 2022 GUIDELINES OF CHINESE SOCIETY OF CLIN ICAL ONCOLOGY ICSCO) HEAD AND NECK CANCER rSt:pOOllffi*tP (csco)csca . iifiilBIfIifiii 2022 GUIDELINES OF CHINESE SOCIETY OF CLINICAL ONCOLOGY (CSCO) HEAD AND NECK CANCER t. ; tl. tl: ti. iJ:. ,t Jit. Jt&f,6JT , ffJf. ! I1l:jHflt&
2、 ( eIP) tm cpl;iilrIihJ5MIrtlls (eseQ) dijnlllRJYtiiill . 2022 / cpl3Ilrlih*RtjJfllst:rllT.fFffSill.iJ!E5.:I* : ABJ1.1:tl:l J1li(ti, 2022.4 TSBN 97R-7- 117-32952-1 T . (D el 11 . CDcp, ill . CD*H1flRIffli -1;JY -=tiii ll IV. CD H739.9 J-62 tf:IlIg 1I:Elft&*11(R erp ,!&j$tK: (2022) m045003 % m Iif AJ
3、I/XXJ ft.#.i.it.llt.V!i;J:jitiil*ijIEl. m ( )jAJIjg/XXJ AJIjg1J8tm11JijIEl tli l:j:IOOIIij*Hljlffli (CSCO) $HljlffliimijWi 2022 * $Zhongguo Linchuang Zhongliu Xuehui (eSeQ )Toujingbu Zhongliu Zhenliao Zhinan 2022 ffi.ffi: 11I1rlH+:fl,p#SZ.iilH# s 7J J; ) =f -B $ 1J,Ji rl a;c 022 lJ-f;:t;: 01 E?J $ i
4、f .:E 11=1 j Zhenliao Zh inan 2022 * $ = 5C-1E 9:D* TBJ3 132 fPsif: 5 1 !t& 1 /X6p,lJ IJ 7-32952-1 ZZO(; !hpDiH2 ( OS) tPD$IItP iiiti!: * m * *ffi.AM ( t:J.EE)iHft7:I) ( 7:JfArgA, ) Bffij T)* D3i B$ t ME t*tjHDI2S:Jfrpf4 B :*:itJirpI2S:JfJl5ztit1Tf4 r:pf4Jf:*:itJirjlI2S:Jfrjlf4 ;*:*:itJi*DI2S:Jfrjlf
5、4 r:p LlJ:*:rjlJJ;r3r:pJl)Jl5zfif4 jMiJ1:rpI2S:Jfmfif4 -M)Oo.:23Y1if 23 MY,2I!hpMcP tt MlIDttJD:tCVt(m!gj+fMcP;t $+t;ft MqWTJicP!-SlIDttJ+rncP t;ft MY,2M)O.:gj*!f)+El , *!;$:E MqWT!YttJtfcP 8:E tfY,2M)O.:gj(m+El R:E M)O.:tf)O-:gj(f)+El , MY,2!YttJ+$l r t I/I M!YttJgfl;t+11 (6 Ii1$ M!YttJJicP!-S!YttJ
6、+rncP ;$ MEIIH&f,3D23Y1+WlIiJf)ll+r:r Ii ;$ MY,2!YttJ(f)+El ifffiiEi M!YttJttJtfcP iiNtlQY 5K H t*:*:rpffilBjCitl!4 5KB$f _b&Y:im:*:BjCjt:tLAR;jCDgY:nmitl!rJlffil4 irJl*f* Li&Y:im:*:jCjt:tLAR;jCDgtl!rnlitl!rJlffil4 B:*:jtE!lf4jCEj:IU4 3t* J3*4:*:jt75jI 1 BjCfif4 *g, LiY:im:*:BjCjt:tLAR;jCfif4 T1JiIE
7、iiHfiS, miljiJ:f:r,BJEiJlSztL O)&*1/t*ffili*, *U):i$*mrjlffilBSiJ:ff;fDig ff:HiiJj , $I1$,*rjlffil (CSCO) BS2js:1Rz-o ilii:F*, 11$,*iJ:fftJjBS*U):i:tjI!;(JJTBSfOJ, (:IPTiJ:ff;*BSPJl.iZtl: , 8T.&*$*, ).mlRttiIEBS*;fDmlR $IllEQ0 ITI), mlR;1t;fD*.&*/FS1jBS.&*$*, CSCO tJjgJBiljmlR&*, fWnfDiJ:ff-F 9:BSPJ
8、tl:rjlffil;gffBSU1;rm=l7Jj 0 JJt, CSCO tJjBS*U):i, g:;j(tij-1II$,*IDJBSiJ:ff mt:lfiS1JiIEiiHfiSfD*:t!;iRm:HJJXiiHfiSj5U , BjfiS8fBSPJti;fD5I;rtHJJX:Iim iIE0 :lfiSj5UF=J , PJtiHBS7J, 11=79 I,&:Ii; iiHfiSj5U$3(F=J, *:t!;iRm:f1, PJtitBS7J, 11=79 II ,&:Ii? ; 1I$,*ffl, miiHfiSj5U/FF=J8S, fl=79111 ,&:Ii?o
9、 CSCO :tJjgT9HI$,*liH JJX;fD CSCO *m, litfJ):i:li&, )1T:*:*tEll$,*R$fflo CSCO tJjIFEQ f1L TiiHfiS, JBiljPJ, g;-8m8S:tJj , -8ftBSII$,*ij;o ft1fJ!tmmU:*:*BS&J m, fti:HiiJj*ffBjiA, ;fRf&*8!mi)(, CSCO tJjBSf4#ti, IEtifDBj5lti0 9 csco ifimiiiiHJi!lHW / 1 csco ifimiinU / 2 1 BDtjlffliifi,ia!i! / 3 :OOBDtj
10、lffliS9 MDT ifif!i: / 4 2 BDtjlffliagiI!Fi!i! / 7I2.1 1$fDirtFi / 8 2.2 WJIIirtFi / 14 2.3 Slffl / 21 2.3.1 mm / 21 2.3.2 OOm (p16- ) 26 2.3.3 OOm (p16+) 30 2.3.4 m / 32 2.3.5 r:ol!Jm / 38 2.3.6 J!D!jm / 42 2.3.7 :;r-:BJ3$)#Bft5$ttj / 45 2.3.8 m(, r:r:,3r:) / 47 3 !l!WlDBWlBag;3fi!i! / 53 3.1 DDiag;
11、3ff / 54 11 !1m 3.1.1 !f!lfflDB9;H7 / 54 6 IItMnj / I3.1.2 gBJlJlmQB9;H7 / 56 6.1 !flJ:lJ.lU 3.2 D o;gfi / 63 6.2 gB. 3.2.1 !f!1lJ3DQB9;:li7 / 63 6.3 :&: j 3.2.2 gBlfflDUB9;gfi / 65 7 iijiJJ / 141 3.3 1Ifj;gfi / 74 3.3.1 !f!1lJ3B9;gfi / 74 3.3.2 gBJlJlB9;gfi / 76 3.4 FO;gfi / 84 3.4.1 !f!lfflTQB9;gf
12、i / 84 3.4.2 gBlfflTQB9;gfi / 86 3.5 .O;gfi / 93 3.5.1 !f!llJ3JlQB9;gfi / 93 3.5.2 WBJlJllQB9;gfi / 95 4 1BiBJ:lgB;.tH,s*tij / 103 5 *ti:!kga;gfi / 109I 5.1 / $,ti:!kg (F.O) e;gfi / 110 5.2 / $tt.O;gfi / 120 12 6 1ID*m I 131I6.1 !:f!.!tIIj1;fi / 132 6.2 f8MDffij1;fi / 134 6.3 a/$t1Dffij1B;fi / 135 7
13、 jHiJj I 141 13 -F=l f iiftJ Meta 51th , *MIJfj:fJlXi. -i5l. (JJ7i! ;: 80% ) F=l fiis Meta 51th , *ID! ifJlXi. :j;*-:tti.R (:tlJ7i! 60%-80% ) ll!J1f -)j)j: ftJ Meta 51th , ,jlID!l!lfJlXiml , i9:HH*ID!Jijj , 1lj -Ximl -i5l. (:tlJ7i!;: 80% ) ll!lif -)j)j:S Meta 51th, ,j ID!ifJlxi. Jf , i9: H r ftJ * I
14、D! WY!Jf , 1tl-Ximl *-:tti5l. ( jm60%- 80% ) if F Xi ml ftJfHdI*, 1H, 7Ci5l. , RiS(* (:tlJ7i! 60% ) III m.fi# csco ifftlliimm ti#m. fij;ljt 1 A liHJi!ijgB 2A l:iHJi!i csco mw-1A iiEt%, &:gMHz*iB-tErpDJ&tHTtfJ 2A iiE_, Im.m#oA: miiE. DJ&tt. .ilifimm., A(*fi.Im.) tfJilim 1 B liHJi!ijgB 2A liEms COmW-1
15、BiiE_, &$*-tErpDJ&tt,*mtfJ 2A iiEm, 11070 II m.:li#o AA: JllJHJln.tiH9, tim.JlIJiiEt% , DJ&ttm; n*Rm.tfJm,*s.DJ flgR, lliDJ1FA II m.m# 2B liHJi!ij 3 liHJi!i n*k.ffl, .*mmtfJilim, .iiEiiE_ffin ,*m.mUADJ.tfJ, Alllm.m# JJ&I1Hft-.l 2A 5fi111i.J1, xE , *:tti,RJt$ft-.l t1;)t nlJ liE tJ5 , frJrti;:, * t!t,
16、f,1!lDJ i U!frpjjBJi fjlaSEWi d!$iM!Ii. ;j; t , MDT :ffJlJJf MDT 8qJl!J:i: *4, xt.f-$f 80-JJ iJ.t!3 Au 80131 J;I;j 7H1 1*fflII o MDT ):;iImji J3t it!.M K,f-$f Fl/:t )(im 1 SHELLENBE neck cancer. 0 2 TABERNA M. and quality of( ;BIi MDT lff.it MDT i:ti:I*J I tlU 5Pf4: 5U!7f4, 19!t fJj, Cl IRfJil1iI7f4
17、 nrpjj J;l;jH p)cfff4 ),MlJ;ITf4 ffi.)J1M4 $WI$.m IEl i.E:7:f4 / ;E9 $ 1El;E E1t IhJ ij, jJii ;E:mEfrl IT ;Eia:4& (:1)!jir;1S(.t;. lllJ E) 1., lItIt:f lIItIt fPt1:.i!5l:1t J6 10 MmBiJMW2t,=BiJ*, ., m*=. ft , mBiJ-., mBiJit,*M/mm, .lliOOW, *m MBiJ*fflff.m/m=*M, AABiJfflffm, n.BiJm ;it.: ffw: 0 MmJili
18、:mMMffMW*m;it.:1t,BiJ&Jili:mmMff., M.* N*BiJM, .ffl$&.m.o 1 SHELLENBERGER TD, WEBER RS. Multidisciplinary team planning for patients with head and neck cancer. Oral Maxillofac Surg Clin North Am, 2018, 30 (4): 435-444. 2 TABERNA M, GIL MONCAYO F, JANE-SALAS E, et at. The multidisciplinary team (MDT)
19、 approach and quality ofcare 1. Front Oncol, 2020, 10: 85. 3 TOWNSEND M, KALLOGJERI D, SCOTT-WITTENBORN N, et al. Multidisciplinary clinic management of head and neck cancer. JAMA Otolaryngol Head Neck Surg, 2017, 143 (12): 1213-1219. 4 LlAO CT, KANG CJ, LEE LY, et al. Association between multidisci
20、plinary team care approach and survival rates in patients with oral cavity squamous cell carcinoma. Head Neck, 2016, 38 (Suppl 1): E15441553. 5 LIGHT T, RASSI EE, MAGGIORE RJ, et al. Improving outcomes in veterans with oropharyngeal squamous cell carcinoma through implementation of a multidisciplina
21、ry clinic. Head Neck, 201 7, 39 (6): 1106-111 2. 6 J BRUNNER M, GORE SM, READ RL, et al. Head and neck multidisciplinary team meetings: effect on patient management. Head Neck, 201 5, 37 (7): 1046-1050. llfl ij JI i fi ft;. !JliJ 2 ciplinary clinic man; (12): 1213-1219. are approach and sur, 38 (Sup
22、pl 1): E 1544.erans with orophaJlinary clinic. Head .eam meetings: effect lIm lIIm PET/CT llfffil B m PET/CT 1H=ltill ._Tmm .T*m (#x;J:JdJi!m)m;) #:i:W#m (#xtlHi.m;) ) :JdYlifj)RtjJ f:!li :it!J-.!.iIWJJlILRru tiJ3:l!I l 3 1o :i1I *-*-o$1.MtB B?t1JT, P-J :fI:l31.6% 510 Q* J!li IlStE$?tIj 1ll Ji!.IR,
23、IHiJI,JU if1l/JIHiJI, 810 Jt :J;UW sEt c :fI:l lllf Ecl1sEt ;It, 0 MRI BiA:ll iffl ML nl iInrr ffli, Jj ifJ!.1f 110 Ji!)J)t1JJJll 0 $:Jj xtTttiEI1iIj;f; IIffi*i1!JT 2.1 11ai*Ilfljtli Im :JdJi!fM* J:sEt CT J:;IsEt MRI illfffiIW sEt CT J:;I185$ CT J:;I(lEt MRI llfifj) sEt CT AAil$5itEjX:-B CT Iifj) B
24、m:i:5Et CT n:i:.Tm(#xt* $J!li) tJJll#m:i:*9=toj(1% (itxtlHi .m;) ifj)*BM:i:m 1+=mllm. (iU;JTPm; ) * Il ij 1IR Et-J i It!i mi mlJ 0 ii U.Ylml9fOO-m.!JiJtl:nq,mlz- I , tEf.ltOO!JHtrrsJ!nJ:5 CT, # HJ!-JEEM!I)13tt .$%ilifiXllfltt.$o rm:X.JTiJjtBlfFBMfI9t!iHt, 1f7tffrJW.ffi PETICT ffi!.:fi-JEf.Jf.J1;1t 1
25、0. 111nuWf.0 I1-liJfJt ffi, :rrmJl5-AAmJ:i4 PETICT i!5l:3f:Y 13 .7% !it:jIf1ilffD1i1-, jtxtTJjfr NO ffi!. 1f.Jf.JI)l1tmifiliJ1flil!i , MTffii!5l:3f:Y 22% (iiJjffll#fBmf3JTJt l12. 13 :XJTiJjfflllf*BMftrmJffi10 :kJ:I3f.IEJiJjmlf!;,f:lli , PET/CT 4X CT TIJ: MRl ffi!.4X8f.J4lJi11 1 14 1o *ffll;IiJjfrj:1
26、&ftD.TM, rm#fMgmMT*M iIfJr 0 ER T T Ill m;4X iWi EIttt&;j?1i=Jffi , I1HJt.*Mfltn.J 1itJl1iftfl-j-= 1Ilmm ( esophagogastroduodenoscopy , EGD ) lt 15. 16 10 j./:ty, -Lm1t:rIlfttlt15: ( panendoscopy ) 3k MT*mMtt=Jffi.o .Jffi;IiJjfr:rrOOrll*1&ftWm ffil *lt,#m#*m*#m#ffl,ftmMfi*Jjfr*! lSI 8l 15-1* *, WJ T
27、 11: iilffN1I1iffl JEilJ7:7t;fn5HIUA.fffJ 1Fn!ztJlllJft m(!l. 17 10 l IjJj & jllJ 3ZiW: 1 LEWIS-JONE National Multic 2 PAN R, ZHU 1J Cancer, 2017, 3 ARGIRlS A, IV 1709. 4 GILLISON ML positive head al 5 GUO L, YANG among the ChiI 6 XU S, SUN B, human papillon tion. Oral Surg 7 XU T, SHEN ( =* Fffll J
28、ltl roo mt 1t JJ1 F*ffi; , wttl:J4: 91iJf 0 10 X;fTm: 3.J!-:fi-B911!:;111Stl: :Bl1jtlj 10, II Jo lW: AX;fTtlfr NOJ!.:ff ft B t,j$ITo m:tzJ ;mWJT7M -T11t -I-=iliiJlfrJ1f1; ( panendoscopy ) :fi !c*-6it1J r$ ;fiLTIJi; 1l;fliEiJtlfr1 1 LEWIS-JONES H, COLLEY S, GIBSON D, Imaging in head and neck cancer:
29、United Kingdom National Multidisciplinary Guidelines, J Laryngol Otol, 2016, 130 (S2): S28-S31. r2 J PAN R, ZHU M, YU C, et aL Cancer incidence and mortality: a cohort study in China, 2008-2013, Int J Cancer, 2017, 141 (7): 1315-1323, 3 J ARGIRIS A, KARAMOUZIS MY, RABEN D, et aL Head and neck cancer
30、. Lancet, 2008, 371 (9625): 16951709, 4 J GILLISON ML, CHATURVEDI AK, ANDERSON WF, et aL Epidemiology of human papillomavirus positive head and neck squamous cell carcinoma, J Clin Oncol, 2015, 33 (29): 3235-3242, r5 J GUO L, YANG F, YIN Y, et aL Prevalence of human papillomavirus type-16 in head an
31、d neck cancer among the Chinese population: a Meta-analysis, Front Oncol, 2018, 8: 619, 6 J XU S, SUN B, ZHOU R, et aL Evaluation of pl6 as a surrogate marker for transcriptionally active human papillomavirus status of oropharyngeal squamous cell carcinoma in an eastern Chinese popula tion, Oral Sur
32、g Oral Med Oral Pathol Oral Radiol, 2020, 129 (3): 236-245, e2, 7 J XU T, SHEN C, WEI Y, et aL Human papillomavirus (HPV) in Chinese oropharyngeal squamous cell carcinoma (OPSCC): A strong predilection for the tonsil. Cancer Med, 2020, 9 (IS): 65 56-6564. tases ofunknov S J SHIELD KD, FERLAY J, JEMA
33、L A, et a1. The global incidence of lip, oral cavity, and pharyngeal CT /MR imagin cancers by subsite in 2012. CA CancerJ Clin, 2017, 67 (l): 51-64. 15 J BUGTER 0, V 9 J GOEL R, MOORE W, SUMER B, et a1. Clinical practice in PET/CT for the management of head and tumors using L neck squamous cell canc
34、er. AJR Am J Roentgenol, 2017, 209 (2): 2S9-303. and meta-analy 10 J YONGKUI L, JIAN L, WANGHAN, et a1. ISFDG-PET/CT for the detection of regional nodal 16 J NI XG, ZHM metastasis in patients with primary head and neck cancer before treatment: a meta-analysis. Surg oesophageal ca Oncol, 2013, 22 (2)
35、: ell-eI6. Otol, 2018, 132 I J J GAO S, Ll S, YANG X, et al. ISFDG PET/CT for distant metastases in patients with recurrent head 17 J PUSZTASZER and neck cancer after definitive treatment. A meta-analysis. Oral Oncol, 2014, 50 (3): J63-167. duction of the r 12 J LONNEUX M, HAMOIR M, REYCHLER H, et a
36、1. Positron emission tomography with ISF fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. J Clin Oncol, 20 I 0, 28 (7): 1190-1 195. llil 13 J LOWE VJ, DUAN F, SUBRAMANIAM RM, et al. Multicenter Trial o
37、f 1 SF fluorodeoxyglucose ij IQ Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and It-J i Wi Negative Predictive Value and Surgical Impact in the NO Neck: Results From ACRJN 6685. J Clin Jfii lll J Oncol, 2019,37 (20): 1704-1712. 14 J LEE JR, KIM JS, ROH JL, et al.
38、Detection of occult primary tumors in patients with cervical metas8): 6556-6564. tases of unknown primary tumors: comparison of (18) F FDG PET/CT with contrast-enhanced CT or avity, and pharyngeal CT/MR imaging-prospective study. Radiology, 2015, 274 (3): 764-77 1. 15 J BUGTER 0 , VAN DE YEN S, HARD
39、ILLO l A, et al. Early detection of esophageal second primary aagement of head and tumors using Lugol chromoendoscopy in patients with head and neck cancer: A systematic review and meta-analysis. Head Neck, 2019, 41 (4): 1122-1130. on of regional nodal 16 NI XG, ZHANG QQ, ZHU JQ, et al. Hypopharynge
40、al cancer associated with synchronous a meta-analysis. Surg oesophageal cancer: risk factors and benefits of image-enhanced endoscopic screening. J Laryngol Otol, 2018, 132 (2): 154-161. ts with recurrent head 17 PUSZTASZERI M, ROSSI ED, BALOCH ZW, et al. Salivary gland fine needle aspiration and in
41、tro0(3): 163-167. duction of the milan reporting system. Adv Anat Pathol, 2019, 26 (2): 84-92. aphy with 18F fluo,d and neck squamous 0-11 95. ; fluorodeoxyglucose nd Neck Cancer and , ACRIN 6685. J Clin s with cervical metas(wlilu Jj -fct-14) *iilii AdH j-fJjil: ,1 JW 1J 13Bff. 9Id (l1#frj,t !# tjJ
42、g M;-fct+) Jil!:I1J13 n-ad llfT,f8f41:litl:bIijf.llf Iijf. (w.ITluJj-fctH) Jil!VJruvNaAdH -R9fl):ffEnlf!j1wiili1H1Fffslfj:Fl:l MIIJlliiT, /:Httl :linlM;ttl tfl fi t,-;,It ;lfr:m: Z t:b 4l:r !#tjJf(M-ftt (w. $f Jj -fct +) *l;J!# tjJg ;1 :fiffl$tM-#l *:I* f8f)13 ,v l,lJ:rY.;1 :kfljWgj:l !#41glliT,f8fi
43、ll :sjt:I lttl:bw.tfijjfJjil:Eri1af13j:m *:tJiYd alMll1 J WfElmI) r II,mt. QfElmi *mi.g1i1t-*IlJl:pfij EGFR BHll.1t1&191IJ_ltiUt. PfEI mI,f!l Jt;fitlf.U* YI$Htpiii EBER JJl3: 1:fL X 1& 191IJ IdHfij 1 J=j EBV r1f:k lljiiUJRmI *m1Hll.1t-*IlJl:pfijllj AR,f!l HER2 i.Hll.1t1&191IJ (HM i1tJl,f;foJt;fit*YI
44、$Htpiii Iljt1tJl,mI) NTRK m:7t)JM:fLXt191IJ (tiM? fHij!;) EBER JJl3:1:fLxt191IJ (ftxt#fELt ELmI) MYB m:7t)Jj(1:fLX1&1JliJ (H:xt Jl, tEmI) MAML2 m:7t)Jj(1:fLX1&1Y!IJ (HM St1t*&:mI ) PLAGI m:7t)Jj(1:fLX1&1JIIJ (HM iffi:fr%riiii 9=t ) 5i :)d:g:rpErmJxtTjWhWfifQ;lilff:J$*m: I 1 Q 7d1;t6t:l(jf-WtiF*, tt1
45、G* mill.ttRill,m*o M*ffltt =F;f:tiF2js:, Il* TJE:1ititifQlj;Tm, :ttt1t1;!UrpjWt*/J, jHUiJJt, tJJ, !lJt, )WJ ffil$ lM, EX:-,1f;lM, l*jstv.ifQ, Lt&Bl)7Hj,ELo Tnmi, llJHij lrpi*JJt, lAmf:ffifIjT1ifMJj(U7MifQ1/;f;g;lilff* 2 1o Tmltlr&i, JiiIJE:1i p16 Er 1l.1.t*B:19!IJfFJ;w1-t1/;ftji12Hlfj.-=5 HPV tEl*,
46、OOllffi*rpjW (ASCO) ifQOOW:JJlll. tJ:M:jt1i#*ffl 70% Er r:pEX:1 BtE UrpjWt ffiHEl) !=J;itWftiFii, :ff;HtB/r:p ,L., PI lV.JE:1i HPV DNA EX: RNA *B:lftl 3. 4 lE. HPV nPltIBJ7M1ifiIifQlVl;g*WfErffSI, 1. mr1ii lJ liD/G9ti5t.*mt19!s*Sc5E;g1-it:1.tBJ;lilff* 5. 610 :ftz:$MJ:li, :tEJ(;%il1T:J$BtPIi1Hi PD-Ll
47、 mm1.tf19!lj, t1i#*fflBtt-7 (combined positive score, CPS)o TJi,Pltljiili, tHIjjj1.t, JiiIJE:1i EBERJJ:iz5t*B:l9!lV.1ij-=5 EBV tEl*o jj :f:ESc EGFR tJLEr#J1/;f1iEElt, PIJE:1i EGFR 1l.1.tt19! 0* llB!J!l Xrr-pt71Jij. 1ifiIrpttiJJtxtT*Wff.m;gifQ1ii;gf1ff*ru1tm:, Ili-HHU,*Y ffil Bl WHO 2017 ttN.BJMJ($:7
48、:f1J7?;& l71 0 X.tTljjli;71JiJJ,J1gfjill.j , JE:1ih:1t:ijs: (AR) ifll HER2 BJ1R. i &i ill1.tt-il9!lj:ffMT1ijnti-i1:BJmlt)ilff, FrT$fBJiWftiFiinI lV.n1-(HxtLjIJtEl*tlJ 81 0 XtTff,! m 7Mi1:f&i, :i1 NTRK :7tJJ:1iz5ttit9!IJ ( tj)lj ETV6-NTRK3 1EI1il) /f;:.Ii$-=5B*li!glHlID JE:1iJJOitWf, t.!. MAML2 if1l
49、PLAGI 8 $,t.)l,J1mir:p 9 0 B*lffilID 7l;0tE tt1t&:t(o;i 1?;&IJifU r:p?;&J.jIJ $%tl:E*j t!.ifQfffii:jjt mt;F:zIs:. 1tJt;fffi dJ!$JlIi EJiJ tiltt , JVj:1f1, )W OO tfIJ T P :JlIi. fffi H)j Tijij r&i. JJiZitH=r p 16 S9:9c. ASCO) ,fQOOm:Fl!l. 1Jr:p,L pHJ,ifriJ HPV tz;. 1iH u1H J!$mm:. tE$, - nbined positive score. j EBV WW!;t:k o 1tli. rlft:J-r R) :fll HER2 EJiJ:9c.J5E EJiJ;t*tlJ 81xtT0 :111JlJMf!Hm Jl JlIi Jttil;JJiJiJ!fi , 3=1: J3.1i t1JTTiffli: TRK 1l1Jjf,tHfIJ EJiJ rPJ iM JJUr, illE1 EBER)ffi iz.xLV.:& MYB ,0 MAML2 fIl PLAG 1 i:tJ:R:lt)ffi .V:x!l;ljT:5HJljii!IT#f Bl:ltJiili , J,RfJlHiiliL Yw*l
个人主页
